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on desktop and tablet PC platforms. Results of the interviews informed the develop-
ment and ﬁ nal testing of a standardized interface that can be used across studies to
facilitate rapid deployment of ePRO studies.
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The Patient-Reported Outcomes Measurement Information System (PROMIS) pro-
vides accurate and efﬁ cient measurement of patient-reported outcomes. Developed in 
English using qualitative methods, PROMIS seeks to measure symptoms, such as pain
and fatigue, and aspects of health-related quality of life across a wide variety of chronic 
diseases and conditions. OBJECTIVES: In order to enable participation of the rapidly 
growing Spanish-speaking population of the USA it was necessary to translate 
PROMIS banks from English into Spanish using methods that would ensure linguistic 
equivalence and cultural appropriateness. METHODS: Five hundred and twenty-two
items were translated into Spanish using the FACIT Multilingual Translation Meth-
odology which consists of the following twelve steps: (1) translatability review of 
existing English items, (2) creation of item deﬁ nitions, (3) two simultaneous forward 
translations,(4) reconciliation of forward translations, (5) back translation of recon-
ciliation, (6) expert review of back translation and previous steps, (7) preliminary 
ﬁ nalization for pilot-testing, (8) harmonization, (9) quality assurance, (10) formatting,
(11) cognitive testing with native speakers of Spanish and (12) analysis and ﬁ nalization 
of translations based on qualitative data collected during pilot-testing. Recognizing 
the need to address diversity within the Spanish-speaking population of the USA, lin-
guists from various Spanish-speaking regions across the globe were recruited to
achieve a universal Spanish translation. RESULTS: Some of the linguistic challenges 
encountered during the translation process as well as the language solutions for resolv-
ing difﬁ culties associated with the cultural and linguistic heterogeneity of the Spanish-
speaking population residing in the USA will be highlighted in this presentation. 
CONCLUSIONS: Future research includes further validation of the Spanish transla-
tions using psychometric testing of the equivalence of banks in English and Spanish,
including assessment of differential item functioning across different cultural groups. 
The translation of additional items into Spanish and into other languages is also 
explored in this presentation.
PMC81
ELECTRONIC PATIENT REPORTED OUTCOMES: FOLLOWING
FDA GUIDANCE FROM A VENDOR PERSPECTIVE
Ross J, Shea E
Almac Clinical Technologies, Yardley, PA, USA
OBJECTIVES: To provide an overview of considerations sponsors/vendors need to
address in order to meet FDA expectations during the planning and implementation 
phases when using Electronic Patient-Reported Outcomes (ePROs) in clinical trials, 
to understand important considerations required in ePRO-use when planning and 
implementing clinical trials, identify essential considerations from a vendor’s perspec-
tive, and following FDA guidance as a vendor or when using a vendor. METHODS:
Sponsors often utilize vendors for the planning and implementation of their trials.
When vendors are involved in these phases with ePRO, it is not only the sponsor’s
responsibility, but also the vendor’s to address considerations to ensure FDA expecta-
tions are met. However, meeting these expectations can be challenging across the
pharmaceutical industry. To assist industry, the FDA released a Draft Guidance to
communicate their perspective on how they evaluate ePRO-use for efﬁ cacy endpoints
in clinical trials and for support claims made in approved product labeling. RESULTS:
Often, sponsors/vendors are unsure how to follow the guidance and are unaware of 
important considerations necessary when incorporating them in clinical trials. These
considerations can include: standardizing data collection with electronic tools, han-
dling missing values, validation, reliability, and responsiveness to clinically signiﬁ cant
differences. EPRO-use in clinical trials requires careful planning and execution. When
these considerations are not satisﬁ ed, the trials can face serious consequences by the
FDA throughout the product development and approval processes. CONCLUSIONS:
This session intends to provide an overview of how FDA ePRO-use expectations 
should be met from the perspective of a vendor during the planning and implementa-
tion phases of clinical trials. Key considerations will be discussed. Fictitious examples 
of what could go wrong will be presented. A summary of recommendations will be
provided on how to follow the FDA guidance and avoid making critical errors when 
employing ePROs in clinical trials.
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OBJECTIVES: Kiswahili (Swahili) is the operative language of 100 million East Afri-
cans. Most patient reported outcome (PRO) measures are developed in the Anglo-
American literature; however, no disease speciﬁ c studies have been published on their
translation into Kiswahili. This project assessed the 1) psychometric properties, and 2) 
cross cultural adaptation of disease speciﬁ c (PRO) measures translated from English .to 
Kiswahili. METHODS: A comprehensive literature and web search identiﬁ ed four
Kiswahili translated PRO measures for study inclusion. PRO measures were included 
for evaluation: if there was at least one peer reviewed English publication providing
psychometric data, and instrument availability. Psychometric instrument evaluation
criteria were based on: conceptual model, practicality (5–15 minutes), depth, reliability
(internal consistency, test-retest: greater than or equal to .7), validity (convergent and 
divergent), and responsiveness (Lohr, 2002). Assessment of the procedures used to
evaluate conceptual and linguistic equivalence was based on recommendations by 
ISPOR Taskforce for Translation and Cultural Adaptation (Wild et al, 2005). RESULTS:
Of the four instruments evaluated: Oral Impacts on Daily Performance (OIDP), Patient
Health Questionnaire – 9 (PHQ-9), World Health Organization Prevention of Blind-
ness and Deafness Visual Functioning-20 (WHO/PBD VF20) and Hopkins Symptom 
Check List-25 (HSCL-25), none met all study criteria for psychometric properties or 
linguistic adaptation procedures. Conceptual model, practicality and internal consis-
tency were met for all scales. In cases where criteria were not met it was predominantly 
due to missing data, e.g, divergent validity was unavailable for the PROs assessed.
CONCLUSIONS: Although attempts to provide good practice guidelines on transla-
tion of PRO instruments have been made, there is need to reach a consensus on these 
guidelines. Researchers involved in the cross cultural adaptation of PRO instruments 
are encouraged to be transparent to enable the complete evaluation and subsequent 
adoption of the translated scale into clinical practice or clinical trials.
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Patient-reported outcomes (PRO) are key endpoint measures to examine and assess 
preferences for health improvements. Conjoint analysis (CA), traditionally used in
marketing studies to examine tradeoffs among attributes, has gained popularity in
health care and PRO studies. However, the use of CA and the type of CA studies
performed in health care has not been fully characterized. In this study, we character-
ized the current trends for CA, classiﬁ ed CA studies by area of focus, examined study
complexity, and provided recommendations for future research. Literature reviews 
were conducted using a multi-database search from 2000 to 2008. Review articles,
methodological, and non-health related CA studies were excluded. Preference studies
were coupled with key words such as: conjoint, health, disease, evaluation, discrete 
choice and outcome(s). Five years were selected for detailed content analysis and re-
checked for accuracy. For the ﬁ ve years examined, there was an upward trend for the 
number of health-related CA studies (2000  22; 2002  39; 2004  38; 2006  56; 
2008  70). However, results from Chi-square analysis revealed no signiﬁ cant differ-
ences among years for the general area of focus for CA studies performed. The largest 
proportion of CA studies consisted of attribute importance, risk, and pharmacoeco-
nomics studies where utility estimates were used to assess willingness-to-pay, quality 
of life, or quality-adjusted life years. Other applications included disease screening, 
value of services, satisfaction, treatment evaluation and service delivery. The use of 
CA to assess PROs in health research has expanded. Recent and more innovative
applications have extended to adherence, disease screening, technology, and value. 
More research is needed to evaluate the usefulness of CA for large database studies
and for economic analyses in health technology assessment.
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OBJECTIVES: Studies powered using a dichotomous endpoint, are often too small to 
ﬁ nd signiﬁ cant differences in quality of life (QoL) or costs. Including the likelihood 
that events in both arms are similar, using either frequentist assumptions or Bayesian 
priors, may increase the power. METHODS: A study of patients with late pain is 
imagined. With therapy, 92% is expected to be pain-free, without 85%. With 2 r 250 
patients, the dichotomous power (pain: yes/no) is 80%. Using the EQ-5D utility score 
it is 40% (with the EQ-5D-pain-dimension at 3 with pain and at 0 without pain and 
the other EQ-5D-dimensions at random population levels). Trials are simulated and
T-tests are calculated based on: 1. QoL of patients with pain is identical in both arms;
2. QoL of patients without pain is identical in both arms; 3. 1  2. 95% credibility 
intervals are calculated using normal priors concerning the difference in QOL (per 
arm) with and without pain. Expectations and precisions are varied as well as base
line probabilities. RESULTS: Making both assumptions, using T-tests, increases the 
power from 40% to 80%. Assumption 1 does so by 2%, assumption 2 by 79%. Both
assumptions contribute equally when the expected pain-free levels are approximately
55% versus 44% instead of 95% versus 82%. The Bayesian model coincides with the
frequentist approach when the precision in the priors concerning the differences in
QoL are set to the extremes (zero or inﬁ nity). Between the extremes the Bayesian
approach offers the ﬂ exibility to compromise. The power increase between the 
extremes can be characterized by a cumulative normal distributions on the log of the 
squared root of the precisions. CONCLUSIONS: Predeﬁ ning logical assumptions in
a QoL analysis may increase the power of a study. The larger the group of patients 
the assumption is applied to, the bigger the power increase.
